RecruitingNCT07491523

Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD

Sponsor

University of Patras

Enrollment

35 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment

Min Age: 18 Years

Interested in this trial?

Get notified about updates and connect with the research team.

DRUGAntifibrotic drugs (nidanib or pirfenidone)

Ssc - ild

DRUGMMF Immunosuppression

we will compare patients with SSc-ILD taking RTX and mmf and patients that are taking RTX,mmf and nintedanib

University of patras

Pátrai, Greece

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT07491523